

6) (Amended) The nanoparticles according to Claim 1, having a size between about 300 and ~~less than~~ about 50 nm.

8) (Amended) The nanoparticles according to Claim 1, wherein the active ingredient is selected from ~~the~~ a group consisting of anticancer substances, antisense molecules, antivirals, antibiotics, proteins, polypeptides, polynucleotides, vaccinating substances, immuno-modulators, steroids, analgesics, antimorphinics, antifungals and antiparasitics.

14) (Amended) A method of preparing nanoparticles according to Claim 1, comprising:

a) preparing a complex of the at least one active ingredient with the at least one compound able to complex ~~the latter~~ said active ingredient in solution in an aqueous or non-aqueous solvent,

b) adding at least one monomer of the polymer in the solution obtained at step (a), and

c) polymerizing the monomer, optionally, in the presence of one or more of a surfactant and/or stabilising agent.

16) (Amended) The method for preparing nanoparticles according to Claim 15, further comprising:

a) preparing a solution of at least one compound able to complex an active ingredient in an aqueous or non-aqueous solvent;

b) gradually adding at least an alkylcyanoacrylate monomer, to the solution of step (a);

c) polymerizing the monomer, ~~optionally~~, in the presence of one or more of a surfactant and/or stabilising agent; and

d) after control and optional purification of the nanoparticles obtained at step (c), incubating the ~~particles~~ nanoparticles in a solution of active ingredient in an aqueous or non-aqueous solvent.

18) (Amended) The method according to Claim 14, wherein, at steps (a), (b) and (d), the solvent is selected such that, while maintaining conditions of polymerization of the polymers, the solubility of the active ingredient and of the compound able to complex the ~~latter~~ said active ingredient is maintained at a maximum.